LEADER 01256nam2-2200421---450- 001 990000920480203316 005 20080626143123.0 035 $a0092046 035 $aUSA010092046 035 $a(ALEPH)000092048USA01 035 $a0092046 100 $a20020129d1967----km-y0itay0103----ba 101 $aeng 102 $aUS 105 $a||||||||001yy 200 1 $a1$fJohn F. Oates, Alan E. Samuel, C. Bradford Welles 210 $aNew Haven$cThe American society of papyrologists$d1967 215 $a288 p.$d29 cm 225 2 $aAmerican studies in papyrology$v2 410 $12001$12001$aAmerican studies in papyrology 461 $10010092046$12001$aYale papyri 606 $aPapiri greci 676 $a091 700 1$aOATES,$bJohn F.$0261189 701 1$aSAMUEL,$bAlan E.$0186811 701 1$aBRADFORD WELLES,$bCharles$0552024 801 0$aIT$bsalbc$gISBD 912 $a990000920480203316 951 $aFONDO$b120832 LM$cFONDO 959 $aBK 969 $aUMA 979 $aPATTY$b90$c20020129$lUSA01$h1154 979 $aPATTY$b90$c20020129$lUSA01$h1155 979 $c20020403$lUSA01$h1735 979 $aPATRY$b90$c20040406$lUSA01$h1703 979 $aPATRY$b90$c20080626$lUSA01$h1431 996 $a1$9971569 997 $aUNISA LEADER 01604nam--2200433---450- 001 990001398320203316 005 20050203152720.0 035 $a000139832 035 $aUSA01000139832 035 $a(ALEPH)000139832USA01 035 $a000139832 100 $a20040206d1980----km-y0itay0103----ba 101 0 $aita 102 $aIT 105 $aa|||||||001yy 200 1 $a<> teatro delle marionette$f[di] Petr G. Bogatyrev$ga cura di Maria Di Salvo$gprefazione di Roberto Leydi$aBurattini, marionette, pupi$ela tradizione italiana$f[di] Italo Sordi 210 $aBrescia$cGrafo$d1980 215 $a154 p.$cill.$d20 cm 225 2 $a<> ricerca folklorica$iTesti$v2 327 1 $aIl teatro ceco delle marionette e dei burattini e il teatro popolare russo ; Sulla correlazione di due sistemi semiotici vicini ; Il teatro delle marionette e il teatro degli attori 410 0$12001$a<> ricerca folklorica$iTesti$v2 423 $1Burattini, marionette, pupi 454 1$12001 461 1$1001-------$12001 676 $a791.5 700 1$aBOGATYREV,$bPetr Grigorevic$0450549 702 1$aLEYDI,$bRoberto 702 1$aSORDI,$bItalo 702 1$aDI SALVO,$bMaria 801 0$aIT$bsalbc$gISBD 912 $a990001398320203316 951 $aXIII.1.B. 80 (Varie coll. 636/2)$b11084 L.M.$cVarie coll. 959 $aBK 979 $aSIAV6$b10$c20040206$lUSA01$h0959 979 $aPATRY$b90$c20040406$lUSA01$h1738 979 $aCOPAT4$b90$c20050203$lUSA01$h1527 996 $aTeatro delle marionette$9910047 996 $aBurattini, marionette, pupi$9930464 997 $aUNISA LEADER 04147nam 2201033z- 450 001 9910557507203321 005 20220111 035 $a(CKB)5400000000044484 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76719 035 $a(oapen)doab76719 035 $a(EXLCZ)995400000000044484 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNew Perspective in Atrial Fibrillation 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 online resource (224 p.) 311 08$a3-0365-1822-3 311 08$a3-0365-1821-5 330 $aIn spite of the large volume of associated research, the pathophysiological mechanisms involved in atrial fibrillation (AF) onset and recurrence remain uncertain. This may explain why the performances of thromboembolic and bleeding prediction scores in AF patients are limited. In the past few years, the concept of atrial cardiopathy has emerged as a promising lead to connect AF to stroke, heart failure, and inflammatory processes: indeed, all of the mechanisms associated with atrial remodeling and the development of atrial cardiopathy are also likely to promote the development of AF. This recent concept of atrial cardiopathy suggests that the real trigger of stroke may be an abnormal atrial substrate rather than atrial rhythm itself. In this setting, AF could be seen as a symptom of atrial cardiopathy rather than a risk factor of stroke. In the absence of validated clinical markers of atrial cardiopathy, the search for the mechanism of AF remains the cornerstone of cardioembolic stroke prevention for now.The aim of this Special Issue is to gather basic research as well as pathophysiological and epidemiological papers focused on the relationship between atrial substrates and atrial fibrillation onset, recurrence, and outcomes. 606 $aMedicine and Nursing$2bicssc 610 $aablation 610 $aacute myocardial infarction 610 $aage 610 $aanticoagulation 610 $aantiplatelet therapy 610 $aarrhythmia 610 $aatrial cardiopathy 610 $aatrial fibrillation 610 $aatrial remodeling 610 $aatrial tachycardia 610 $aautonomic nervous system 610 $abiomarkers 610 $ableeding risk 610 $aBNP 610 $acardiac 610 $acardiac ablation 610 $acardiac remodeling 610 $acatheter ablation 610 $acircRNA 610 $aconvergent ablation 610 $acoronary artery bypass grafting 610 $acoronary artery disease 610 $adementia 610 $aearly-onset 610 $aelderly 610 $aelectroporation 610 $aepicardial adipose tissue 610 $aganglionated plexi 610 $aheart 610 $aheart rate variability 610 $ahybrid ablation 610 $ahypertension 610 $airreversible electroporation 610 $aischemic stroke 610 $aleft atrial appendage closure 610 $aleft atrial appendage occlusion 610 $amechanism 610 $amiRNA 610 $amitochondria 610 $amortality 610 $amtDNA 610 $an/a 610 $anew oral anticoagulants 610 $aNOAC 610 $aoutcome 610 $aparoxysmal atrial fibrillation 610 $apersistent atrial fibrillation 610 $apharmacotherapy 610 $aposterior wall 610 $apostoperative atrial fibrillation 610 $aprevention 610 $aprognosis 610 $apulsed field ablation 610 $arisk factor 610 $aSNPs 610 $aspatiotemporal dispersion 610 $astatin 610 $aVKA 615 7$aMedicine and Nursing 700 $aGuenancia$b Charles$4edt$01290021 702 $aGuenancia$b Charles$4oth 906 $aBOOK 912 $a9910557507203321 996 $aNew Perspective in Atrial Fibrillation$93021308 997 $aUNINA